• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Hirosaki International Forum of Medical Science >Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats
【24h】

Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats

机译：囊叠氮杂物对6-羟基胺损伤大鼠纹状体L-多氮衍生细胞外多巴胺水平和芳族L-氨基酸脱羧酶活性的影响

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We investigated the influence of benserazide on the central AADC activity in rats with dopaminergic denervation and determined changes in extracellular dopamine (DA) levels after benserazide and l-DOPA administration. First, using in vivo microdialysis technique, we measured extracellular DA levels in the striatum of 6-hydroxydopamine (6-OHDA)-lesioned rats treated with benserazide and l-DOPA. Second, we measured AADC activity in the striatal tissue after benserazide administration. Although 5, 10 and 50 mg/kg benserazide showed an identical increase in exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels was significantly prolonged by benserazide dose-dependently. AADC activity in the denervated striatal tissues showed a significant decrease by 10 and 50 mg/kg benserazide. These results suggest that benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous l-DOPA. Central activity of AADC inhibitors should be taken into consideration when they are used both in experimental and clinical studies on Parkinson's disease. ?2003 Elsevier Science B.V. All rights reserved.
机译：我们调查了Benserazide对大鼠中央AADC活性的影响，并确定了Benserazide和L-DOPA给药后细胞外多巴胺（DA）水平的确定。首先，使用体内微透析技术，我们测量用囊植物和L-DOPA处理的6-羟基多胺（6-OHDA） - leSion大鼠纹状体中的细胞外DA水平。其次，我们在培人杂氮施用后测量纹纹体组织中的AADC活性。虽然5,10和50mg / kg丧失突甲哒嗪显示出外源性L-DOPA衍生的细胞外DA水平相同的增加，但依赖性的囊叠剂量达到达到峰DA水平的时间。神经内侧组织中的AADC活性显示出10和50mg / kg囊植物的显着降低。这些结果表明，Benserazide降低了患有尼格松证神经的大鼠纹状体中的中央AADC活性，这导致外源L-DOPA的代谢的变化。当帕金森病的实验和临床研究中使用时，应考虑AADC抑制剂的中心活动。 ？2003年elestvier science b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号